Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

December 6, 2019December 6, 2019

Dosing Begins in Phase 2 Trial of CNM-Au8, Potential Therapy for Dopaminergic Neurons

News

A pilot Phase 2 study evaluating CNM-Au8, an investigational Parkinson’s treatment aiming to protect nerve cells, has started dosing patients, the therapy’s developer, Clene Nanomedicine, announced. The open-label REPAIR-PD (NCT03815916) clinical trial ... Read more

December 4, 2019December 4, 2019

RightEye’s Vision System for Early Diagnosis Named ‘Breakthrough Device’ by FDA

News

RightEye’s Vision System, an advanced eye-tracking device that measures eye tremors to help diagnose Parkinson’s disease at early stages, has been designated a breakthrough device by the U.S. Food and Drug Administration. ... Read more

November 26, 2019November 27, 2019

Sunovion Re-Submits Approval Request for APL-130277 to FDA for Treating Parkinson’s Off Periods

News

Sunovion Pharmaceuticals has re-submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA), once again seeking the approval of its below-the-tongue formulation of apomorphine — ... Read more

November 19, 2019November 19, 2019

Gut Inflammation May Increase Risk for Parkinson’s Disease, Review Study Suggests

News

Inflammation in the gut, a hallmark of autoimmune disorders such as inflammatory bowel disease, may contribute to an earlier risk of developing Parkinson’s disease (PD), according to a recent ... Read more

October 29, 2019October 29, 2019

Alzheimer’s Treatment Not Seen to Aid Patients’ Balance After 6 Weeks, Small Study Suggests

News

Treatment with Aricept (donepezil) for six weeks does not seem to improve balance, either while standing or walking, for Parkinson’s patients with a minimal history of falls, according to ... Read more

October 29, 2019October 29, 2019

Potential Therapy for Dopaminergic Neurons, CNM-Au8, Enter Phase 2 Trial in Parkinson’s Patients

News

CNM-Au8, an investigational therapy by Clene Nanomedicine, improved the survival of dopaminergic neurons, helped prevent loss of mitochondria, and rescued motor function in a rat model of Parkinson’s disease, ... Read more

October 17, 2019October 31, 2019

Nourianz Now Available in US as Add-on to Carbidopa/Levodopa to Treat Parkinson’s Off Periods

News

Kyowa Kirin’s Nourianz (istradefylline) tablets are now available in the United States as an add-on treatment for off periods in Parkinson’s disease patients on a carbidopa/levodopa regimen. Off periods — ... Read more

October 14, 2019October 14, 2019

Researchers Using Real-time Brain Mapping to Search for Therapeutic Targets in PD

News

Using its brain mapping platform, Inscopix will team up with researchers at the Broad Institute of MIT and Harvard to investigate how changes in brain activity alter the functioning ... Read more

October 3, 2019October 3, 2019

Silverstein Foundation, Q-State Launch Company Aiming to Treat Parkinson’s Linked to GBA Mutations

News

The Silverstein Foundation for Parkinson’s with GBA together with Q-State Biosciences have launched Chamishi Therapeutics, a company aiming to develop innovative treatments for Parkinson’s disease and other neurodegenerative diseases. Chamishi ... Read more

September 18, 2019September 18, 2019

CRISPR/Cas9’s Potential in Better Understanding and Treating Parkinson’s Focus of Review Study

News

In a recent review, scientists highlight the potential of gene editing technologies like CRISPR/Cas9 to not only understand the molecular mechanisms behind Parkinson’s disease, but also identify new targets ... Read more

Pin It on Pinterest